Sandbox Reserved 712: Difference between revisions
From Proteopedia
Jump to navigationJump to search
| Line 13: | Line 13: | ||
Because of its importance for the life-cycle of the retrovirus, HIV-PR are the major target for anti-HIV treatment. | Because of its importance for the life-cycle of the retrovirus, HIV-PR are the major target for anti-HIV treatment. | ||
HIV protease inhibitors are the most potent agens used in anti-HIV treatment. However it occurs that HIV-PR develop a resistance to the inhibitor. | HIV protease inhibitors are the most potent agens used in anti-HIV treatment. However it occurs that HIV-PR develop a resistance to the inhibitor. <ref> PMID:12543689 </ref> | ||
3ggu (also PRdrv5) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref> PMID:19535439 </ref> | 3ggu (also PRdrv5) is a mutated clinically derived PR that shows phenotypical resistance to darunavir. Darunavir is a human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) which has inhibiting effects on many HIV type 1 PR variants that show resistance to earlier-generation-PIs. <ref> PMID:19535439 </ref> | ||
